Humanized bispecific antibodies retargeting of lymphocytes against tumor cells

DOI Web Site 39 References
  • Kumagai Izumi
    Department of Biomolecular Engineering, Graduate School of Engineering, Tohoku University
  • Asano Ryutaro
    Department of Biomolecular Engineering, Graduate School of Engineering, Tohoku University

Bibliographic Information

Other Title
  • バイオ素材による創薬とＤＤＳ　　リンパ球とがん細胞を認識するヒト型二重特異性抗体
  • リンパ球とがん細胞を認識するヒト型二重特異性抗体
  • リンパキュウ ト ガン サイボウ オ ニンシキスル ヒトガタ ニジュウ トクイセイ コウタイ

Search this article

Abstract

Antibodies play a central role in humoral immunity and have been developed not only as reagents for the detection and diagnosis but also as clinical products due to its high affinity and specificity. Approximately 20 therapeutic antibodies have been approved by the FDA, and there are more than 100 additional antibodies in clinical development. In the development of antibody drugs, problems such as limited efficacy and high production costs have become so serious that attempts are now being made to construct highly effective and potent recombinant antibodies from human and/or humanized protein fragments. In this review, we focused on bispecific antibodies retargeting of lymphocytes against tumor cells and introduced its perspective as a novel reagent for cancer therapy.

Journal

  • Drug Delivery System

    Drug Delivery System 23 (5), 518-525, 2008

    THE JAPAN SOCIETY OF DRUG DELIVERY SYSTEM

References(39)*help

See more

Related Projects

See more

Keywords

Details 詳細情報について

Report a problem

Back to top